Arbutus Biopharma

Arbutus Biopharma

ABUS· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +47.1% in FY2025

Lindsay Androski is the CEO of Arbutus Biopharma and was paid $1.4M in FY2025 (Dec).

Pay$100 in the stock at the end of FY23 → $192
CEO pay is from each Arbutus Biopharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives4

See all
  1. 1Michael McElhaughFY2025
  2. 2Tuan NguyenFY2025
  3. 3David C. HastingsFY2025
  4. 4Lindsay AndroskiFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Arbutus Biopharma paid its 4 named executives $9.6M in total in FY2025 (Dec). CEO Lindsay Androski was paid $1.4M of that.

Name
Michael McElhaughFormer Interim President and Chief Executive OfficerNot disclosed
Tuan NguyenChief Financial OfficerNot disclosed
David C. HastingsFormer Chief Financial OfficerNot disclosed
Lindsay AndroskiPresident and Chief Executive OfficerNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Arbutus Biopharma. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Activity

Filings6

See all
Proxy statementDEF 14AApr 14, 2026FY2025
Annual report10-KMar 23, 2026FY2025
Proxy statementDEF 14AApr 4, 2025FY2024
Annual report10-KMar 27, 2025FY2024
Proxy statementDEF 14AApr 10, 2024FY2023
Annual report10-KMar 5, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data